February 18, 2014

Specialty Pharmacy Times — As payers struggle to rein in the runaway costs of specialty medications, one area of significant cost savings could be better site-of-care management for infused therapies. Infused therapies are typically used for immune deficiency and inflammatory conditions such as rheumatoid arthritis (RA). About 40% of infused therapies for inflammatory conditions and 38% for immune deficiency are administered in a hospital outpatient setting, where they can cost significantly more than home infusion.